ARTHEx Biotech Announces FDA Rare Pediatric Designation (RPD) of ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)

USA - English

• France - Français
• España - español

VALENCIA, Spain, Nov. 7, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Designation (RPD) to ATX-01 for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder.  In addition to RPD, ARTHEx has previously received Orphan Drug Designation (ODD) for ATX-01 in DM1 from the US and European authorities. 

ATX-01 is an antimiR oligonucleotide designed to inhibit microRNA 23b (miR-23b), which is a natural repressor of MBNL protein expression. In DM1 patients, loss of MBNL protein function caused by (1), reduced expression of MBNL proteins due to miR-23b upregulation and (2), MBNL sequestration in toxic DMPK mRNA, leads to a spliceopathy, which is the cause of symptomatology in DM1 patients.

In human DM1 myoblast cell lines obtained from patients with a wide range of CTG repeat lengths, ATX-01 increased MBNL protein expression and reduced significantly toxic DMPK mRNA, correcting critical cellular defects such as spliceopathy.  ATX-01 is currently being evaluated in the Phase I-IIa ArthemiR™ trial for the treatment of DM1.

ATX-01 is an oleic acid-conjugated antisense oligonucleotide with preferential delivery to target tissues (muscle & brain).  Given the combination of its mechanism of action (increased MBNL protein level and reduction of toxic DMPK mRNA) and its ability, in animal models, to cross the blood brain barrier, it is being investigated for different forms of DM1, from congenital through to adult forms.

Several DM1 phenotypes are recognized including Congenital DM1, Childhood DM1, Adult or Classic DM1, and Mild or Late Onset DM1. Generally pediatric forms have a higher number of CTG repeats, manifest symptoms earlier, and present with a qualitatively different phenotype, including greater brain-related symptomatology, than adult DM1. In addition, the serious and life-threatening manifestations of DM1 primarily affect children and adolescents.

"Myotonic Dystrophy Type 1 is an aggressive and challenging neuromuscular disorder affecting not only adults, but also children and has no approved treatment option for any age group," said Judith Walker, M.D., Chief Medical Officer of ARTHEx.  "By leveraging its dual mechanism of action to increase levels of MBNL protein levels and reduce DMPK toxic mRNA, and its ability to be efficiently delivered, in animal, to muscle and brain, we believe that ATX-01 has the potential to become a best-in-class treatment for DM1.  Along with our Orphan Drug Designations in both the US and Europe, this Rare Pediatric Disease Designation further strengthens and broadens our development plans for ATX-01 across the full spectrum of DM1."

According to US regulations, a "rare pediatric disease" is a disease that meets the following criteria: (A) The disease is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, and, (B) The disease is a rare disease or condition, within the meaning of US law.

The FDA awards Rare Pediatric Disease (RPD) designation in a bid to incentivise Sponsors, such as ARTHEx to develop drugs for children with rare diseases. One of the key benefits of holding RPD designation is the ability to apply for a Priority Review Voucher (PRV) if certain conditions are met.

About ARTHEx Biotech

ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression.  The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1.  The Company headquarters are in Valencia, Spain.

For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.

SOURCE ARTHEx Biotech